ClinicalTrials.gg
RecruitingNCT07221474INTerpath-13Updated Nov 12, 2026

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

A Phase 2 interventional study of Intismeran Autogene and Pembrolizumab in Squamous Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 56 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 12, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc — 14 open to participants now, 26 under way, 18 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck & Co., Inc.

Planned enrollment
41st of 88
180 · median 149
Started
2025
with 4 others
Phase 2
24 of 91
2 open now
Primary completion
2029-07
later than 14 of 25 live
Registered
88th of 91
by date

Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 41st largest by planned enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2025, is one of 24 in phase 2, reaches primary completion later than 14 of the 25 other live ones, and was the 88th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer.

The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.

03

Conditions studied

  • Squamous Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion Criteria include, but are not limited to:

  • Has a or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) (Stage IV: M1a, M1b, M1c1, M1c2, AJCC Staging Manual, Version 9). NOTE: Mixed tumors will be characterized by the predominant cell type; however, small cell elements are not permitted.
  • Has per Response Criteria in Solid Tumors Version 1.1 ( 1.1) as assessed by the local site investigator/radiology
  • Has provided a tissue sample that is collected either at the time of or after the diagnosis of disease AND is from a site not previously irradiated
  • Adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • surface antigen (HBsAg) positive participants are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization
  • Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable. NOTE: Participants must have completed curative antiviral therapy at least 4 weeks prior to randomization
  • Has an (ECOG) performance status of 0 to 1 assessed within 7 days before randomization
  • Has a of at least 3 months
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

Exclusion Criteria include, but are not limited to:

  • Is -infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has received prior treatment with a cancer vaccine, including another personalized cancer vaccine (PCV)
  • Has received prior systemic anticancer therapy for their NSCLC
  • Has received prior therapy with an anti-programmed cell death 1 protein (), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor. NOTE: Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent in the or adjuvant setting for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring
  • Has received radiation therapy to the lung that is >30 gray within 6 months of start of study intervention
  • Has received a live or within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
  • Has received an agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study intervention
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has severe (≥Grade 3) to V940, pembrolizumab, or any of the protocol allowed chemotherapy agents and/or any of their
  • Has active disease that has required systemic treatment in the past 2 years
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has active infection requiring systemic therapy
  • Has a history of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Intismeran Autogene + Pembrolizumab + Chemo

    Induction phase: Participants receive pembrolizumab 400 mg intravenous (IV) infusion on Day 1 of a six week cycle plus a platinum doublet chemotherapy regimen (carboplatin area under the curve (AUC) 6 or 5 mg/mL/min IV infusion every 3 weeks (Q3W) × 2 doses combined either with paclitaxel 200 or 175 mg/m\^2 IV infusion Q3W × 2 doses, OR with nab paclitaxel 100 mg/m\^2 IV infusion weekly × 6 doses). Intismeran Autogene 1 mg intramuscular (IM) injection is administered on Days 1 and 22 of Cycle 2 Induction (Q3W) for up to 2 doses. Maintenance phase: Participants receive pembrolizumab 400 mg IV infusion on Day 1 every 6 weeks (Q6W) for up to 15 doses. Intismeran Autogene 1 mg IM injection is administered on Days 1 and 22 (Q3W) for up to 7 doses during maintenance.

    Biological: Intismeran Autogene · Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-paclitaxel

  • Experimental
    Placebo + Pembrolizumab + Chemo

    Induction phase: Participants receive pembrolizumab 400 mg intravenous (IV) infusion on Day 1 of a six week cycle plus a platinum doublet chemotherapy regimen (carboplatin area under the curve (AUC) 6 or 5 mg/mL/min IV infusion every 3 weeks (Q3W) × 2 doses combined either with paclitaxel 200 or 175 mg/m\^2 IV infusion Q3W × 2 doses, OR with nab paclitaxel 100 mg/m\^2 IV infusion weekly × 6 doses). Placebo intramuscular (IM) injection is administered on Days 1 and 22 of Cycle 2 Induction (Q3W) for up to 2 doses. Maintenance phase: Participants receive pembrolizumab 400 mg IV infusion on Day 1 every 6 weeks (Q6W) for up to 15 doses. Placebo IM injection is administered on Days 1 and 22 (Q3W) for up to 7 doses during maintenance.

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-paclitaxel · Other: Placebo

Interventions

  • 1 mg Intramuscular (IM) Injection

    Also known as: mRNA-4157, V940

  • BiologicalPembrolizumab

    200 mg IV Infusion

    Also known as: MK-3475, KEYTRUDA®

  • Area Under the Curve (AUC) either 6 or 5 (mg/mL/min) IV Infusion

  • 200 or 175 mg/m\^2 IV Infusion

  • 100 mg/m\^2 IV Infusion

  • OtherPlacebo

    Placebo matched to Intismeran Autogene IM injection

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

    Time frame: Up to ~32 months

  2. Overall Survival (OS)

    OS, defined as the time from randomization to death due to any cause. OS will be presented.

    Time frame: Up to ~42 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.

    Time frame: Up to ~26 months

  2. Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to ~42 months

  3. Number of Participants who Experience an Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

    Time frame: Up to ~42 months

  4. Number of Participants who Discontinue Study Intervention Due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study intervention due to an AE will be presented.

    Time frame: Up to ~24 months

07

Study locations

56 of 56 sites recruiting
  • Moffitt Cancer Center ( Site 0021)
    Tampa, Florida 33612, United States
    Recruiting
    • Study Coordinator · Contact813-745-7363
  • VA Ann Arbor Healthcare System ( Site 0019)
    Ann Arbor, Michigan 48105, United States
    Recruiting
    • Study Coordinator · Contact734-769-7100
  • Washington University School of Medicine ( Site 0024)
    St Louis, Missouri 63110, United States
    Recruiting
    • Study Coordinator · Contact314-362-5000
  • Valley Health Systems - Ridgewood Campus ( Site 0010)
    Paramus, New Jersey 07652, United States
    Recruiting
    • Study Coordinator · Contact201-634-5578
  • New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001)
    Albany, New York 12206, United States
    Recruiting
    • Study Coordinator · Contact518-489-0044
  • Cleveland Clinic - Ohio ( Site 0016)
    Cleveland, Ohio 44195, United States
    Recruiting
    • Study Coordinator · Contact216-445-7855
  • Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025)
    Corvallis, Oregon 97330, United States
    Recruiting
    • Study Coordinator · Contact541-768-4950
  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
    Nashville, Tennessee 37203, United States
    Recruiting
    • Study Coordinator · Contact615-961-9469
  • Texas Oncology - Central/South Texas ( Site 8002)
    Austin, Texas 78745, United States
    Recruiting
    • Study Coordinator · Contact512-427-9400
  • Virginia Cancer Specialists ( Site 0003)
    Fairfax, Virginia 22031, United States
    Recruiting
    • Study Coordinator · Contact730-280-5390
  • Swedish Medical Center-Swedish Cancer Institute ( Site 0023)
    Seattle, Washington 98104, United States
    Recruiting
    • Study Coordinator · Contact855-922-6237
  • Hospital Italiano de Buenos Aires ( Site 0200)
    Ciudad Autonoma de Buenos Aires., Buenos Aires C1199ABB, Argentina
    Recruiting
    • Study Coordinator · Contact+541149590497
  • Instituto Alexander Fleming ( Site 0201)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
    Recruiting
    • Study Coordinator · Contact+541132218956
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
    Recruiting
    • Study Coordinator · Contact+5492235937663
  • Clinica Adventista Belgrano ( Site 0206)
    Caba., Buenos Aires F.D. C1430EGF, Argentina
    Recruiting
    • Study Coordinator · Contact+5491140141500
  • Fundacion Estudios Clinicos ( Site 0207)
    Rosario, Santa Fe Province S2000DSV, Argentina
    Recruiting
    • Study Coordinator · Contact+5493413168137
  • Sanatorio Parque ( Site 0203)
    Rosario, Santa Fe Province S2000DSV, Argentina
    Recruiting
    • Study Coordinator · Contact+543874044942
  • Westmead Hospital ( Site 0400)
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Study Coordinator · Contact+61298455555
  • Princess Alexandra Hospital ( Site 0403)
    Woolloongabba, Queensland 4102, Australia
    Recruiting
    • Study Coordinator · Contact+61731762111
  • One Clinical Research ( Site 0402)
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • Study Coordinator · Contact+6186279 9466
  • Centro de Estudios Clínicos SAGA ( Site 0307)
    Santiago, Region M. de Santiago 7500653, Chile
    Recruiting
    • Study Coordinator · Contact+56991612199
  • Fundación Arturo López Pérez ( Site 0300)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56224205098
  • Bradfordhill ( Site 0301)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact+56 2 29490970
  • Bradford Hill Norte ( Site 0308)
    Antofagasta, 1263521, Chile
    Recruiting
    • Study Coordinator · Contact56442023631
  • Centre Georges François Leclerc ( Site 0805)
    Dijon, Cote-d Or 21000, France
    Recruiting
    • Study Coordinator · Contact+33345348051
  • Institut de Cancérologie de l'Ouest ( Site 0801)
    Angers, Pays de la Loire Region 49055, France
    Recruiting
    • Study Coordinator · Contact+33 (0)2.44 85 35 54
  • CHU GABRIEL MONTPIED ( Site 0802)
    Clermont-Ferrand, Puy-de-Dome 63001, France
    Recruiting
    • Study Coordinator · Contact+33473754440
  • Ospedale Santa Maria delle Croci-Dipartimento Oncoematologico ( Site 1004)
    Ravenna, Emilia-Romagna 48121, Italy
    Recruiting
    • Study Coordinator · Contact+390544285247
  • Ospedale San Raffaele-Oncologia Medica ( Site 1002)
    Milan, 20132, Italy
    Recruiting
    • Study Coordinator · Contact+390226436633
  • Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 1000)
    Milan, 20133, Italy
    Recruiting
    • Study Coordinator · Contact+390223903829
  • AO Santa Maria della Misericordia-Oncology Department ( Site 1005)
    Perugia, 06132, Italy
    Recruiting
    • Study Coordinator · Contact+390755782661
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1001)
    Roma, 00168, Italy
    Recruiting
    • Study Coordinator · Contact00390630154277
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1101)
    Poznan, Greater Poland Voivodeship 60-569, Poland
    Recruiting
    • Study Coordinator · Contact+48616654242
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1100)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
    • Study Coordinator · Contact+48225463066
  • Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1102)
    Przemyśl, Podkarpackie Voivodeship 37-700, Poland
    Recruiting
    • Study Coordinator · Contact+48166775000
  • National Cancer Center ( Site 0504)
    Goyang-si, Kyonggi-do 10408, South Korea
    Recruiting
    • Study Coordinator · Contact+82319200114
  • Seoul National University Bundang Hospital ( Site 0500)
    Seongnam-si, Kyonggi-do 13620, South Korea
    Recruiting
    • Study Coordinator · Contact+82317877071
  • Chungbuk National University Hospital-Internal medicine ( Site 0501)
    Cheongju-si, North Chungcheong 28644, South Korea
    Recruiting
    • Study Coordinator · Contact043-269-6015
  • Asan Medical Center ( Site 0503)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230103215
  • Samsung Medical Center ( Site 0502)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact+82234101132
  • ICO L Hospitalet ( Site 1311)
    Hospitalet, Barcelona 08907, Spain
    Recruiting
    • Study Coordinator · Contact+34 93 260 77 44
  • Hospital Jerez de la Frontera-UGC Oncología ( Site 1315)
    Jerez de la Frontera, Cadiz 11407, Spain
    Recruiting
    • Study Coordinator · Contact956 03 22 44
  • Hospital Universitari Vall d''Hebron ( Site 1310)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34 93 254 3450
  • Hospital Ramon y Cajal ( Site 1314)
    Madrid, 28034, Spain
    Recruiting
    • Study Coordinator · Contact+34 91 336 82 63
  • Hospital Clinico San Carlos... ( Site 1313)
    Madrid, 28040, Spain
    Recruiting
    • Study Coordinator · Contact+34 913303000
  • Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1312)
    Seville, 41009, Spain
    Recruiting
    • Study Coordinator · Contact+34 671560092
  • China Medical University Hospital ( Site 0606)
    Taichung, 404, Taiwan
    Recruiting
    • Study Coordinator · Contact+886422052121
  • National Cheng Kung University Hospital ( Site 0601)
    Tainan, 70403, Taiwan
    Recruiting
    • Study Coordinator · Contact+88662353535
  • Mackay Memorial Hospital ( Site 0604)
    Taipei, 104, Taiwan
    Recruiting
    • Study Coordinator · Contact+886225433535
  • National Taiwan University Cancer Center (NTUCC) ( Site 0600)
    Taipei, 106, Taiwan
    Recruiting
    • Study Coordinator · Contact+886223220322
  • Taipei Veterans General Hospital ( Site 0602)
    Taipei, 11217, Taiwan
    Recruiting
    • Study Coordinator · Contact+88628712121
  • Chang Gung Medical Foundation-Linkou Branch ( Site 0605)
    Taoyuan, 33305, Taiwan
    Recruiting
    • Study Coordinator · Contact+88633281200
  • Hacettepe Universitesi Tıp Fakultesi ( Site 1400)
    Ankara, 06230, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+905436067759
  • Memorial Ankara Hastanesi ( Site 1401)
    Ankara, 06520, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+9005321332009
  • Ankara Bilkent Şehir Hastanesi ( Site 1402)
    Ankara, 06800, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+905384724282
  • Koç Üniversitesi Hastanesi ( Site 1403)
    Istanbul, 34010, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact+905369410661
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2029, 42 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 42 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2025
First posted
Oct 28, 2025
StartActual
Dec 12, 2025
Primary completionEst.
Jul 2, 2029
CompletionEst.
May 6, 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Chile, 1 Italy)
  • Fundación Arturo López Pérez ( Site 0300) · Santiago, Chile
  • AO Santa Maria della Misericordia-Oncology Department ( Site 1005) · Perugia, Italy
Show 1 removed
  • FALP ( Site 0300) · Santiago, Chile
across 2 updates, Oct 1, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • AO Santa Maria della Misericordia-Oncology Department ( Site 1005) · Perugia, Italy
    + 2 other changes: verification date and references
  2. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Fundación Arturo López Pérez ( Site 0300) · Santiago, Chile
    Show 1 removed
    • FALP ( Site 0300) · Santiago, Chile
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07221474
Collaborators
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 28, 2025
Start date
Dec 12, 2025
Primary completion
Jul 2, 2029 (estimated)
Completion
May 6, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Intismeran autogene

Start the discussion